CN113694063A - Composition and application thereof - Google Patents
Composition and application thereof Download PDFInfo
- Publication number
- CN113694063A CN113694063A CN202111009764.3A CN202111009764A CN113694063A CN 113694063 A CN113694063 A CN 113694063A CN 202111009764 A CN202111009764 A CN 202111009764A CN 113694063 A CN113694063 A CN 113694063A
- Authority
- CN
- China
- Prior art keywords
- nsc228155
- hair
- transdermal
- preparation
- alopecia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 8
- ICCFXXDUYSPKOL-UHFFFAOYSA-N 7-nitro-4-(1-oxidopyridin-1-ium-2-yl)sulfanyl-2,1,3-benzoxadiazole Chemical compound C12=NON=C2C([N+](=O)[O-])=CC=C1SC1=CC=CC=[N+]1[O-] ICCFXXDUYSPKOL-UHFFFAOYSA-N 0.000 claims abstract description 24
- 201000004384 Alopecia Diseases 0.000 claims abstract description 24
- 231100000360 alopecia Toxicity 0.000 claims abstract description 14
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims abstract description 10
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims abstract description 10
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000012190 activator Substances 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 230000003676 hair loss Effects 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- -1 azone compound Chemical class 0.000 claims description 4
- 239000006184 cosolvent Substances 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 208000024963 hair loss Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 208000004631 alopecia areata Diseases 0.000 claims description 3
- 201000002996 androgenic alopecia Diseases 0.000 claims description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229960004756 ethanol Drugs 0.000 claims description 2
- 229940044949 eucalyptus oil Drugs 0.000 claims description 2
- 239000010642 eucalyptus oil Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 229940041616 menthol Drugs 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- CIDGKBCDYFUZNN-UHFFFAOYSA-N sulfinylmethanone Chemical compound O=C=S=O CIDGKBCDYFUZNN-UHFFFAOYSA-N 0.000 claims description 2
- 150000003505 terpenes Chemical class 0.000 claims description 2
- 235000007586 terpenes Nutrition 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims 1
- 229940116229 borneol Drugs 0.000 claims 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims 1
- 210000004209 hair Anatomy 0.000 abstract description 13
- 210000003780 hair follicle Anatomy 0.000 abstract description 10
- 230000003698 anagen phase Effects 0.000 abstract description 8
- 210000002615 epidermis Anatomy 0.000 abstract description 7
- 210000000442 hair follicle cell Anatomy 0.000 abstract description 4
- 230000003779 hair growth Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 210000000130 stem cell Anatomy 0.000 abstract description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract description 2
- 230000032823 cell division Effects 0.000 abstract description 2
- 210000000170 cell membrane Anatomy 0.000 abstract description 2
- 210000000805 cytoplasm Anatomy 0.000 abstract description 2
- 238000006471 dimerization reaction Methods 0.000 abstract description 2
- 210000002919 epithelial cell Anatomy 0.000 abstract description 2
- 206010020718 hyperplasia Diseases 0.000 abstract description 2
- 230000003780 keratinization Effects 0.000 abstract description 2
- 230000000149 penetrating effect Effects 0.000 abstract description 2
- 230000026731 phosphorylation Effects 0.000 abstract description 2
- 238000006366 phosphorylation reaction Methods 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000012224 working solution Substances 0.000 description 3
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical class CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229940084577 EGFR agonist Drugs 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a composition and application thereof. The application is the application of an EGFR activator NSC228155 in preparing external medicines, cosmetics or daily chemical products, and can solve the problems of alopecia or hair scarcity. NSC228155, after penetrating the epidermis, rapidly penetrates the cell membrane and disperses in the cytoplasm and the nucleus, binds to the dimerization domain II of the sfegfr, regulates the tyrosine phosphorylation of the EGFR, and stimulates the EGFR in the hair follicle. After EGFR is combined, a series of biochemical activities in cells can be caused, epidermis and epithelial cells can be stimulated, epidermis hyperplasia and keratinization can be promoted, cell division, particularly hair follicle cells, can be strongly promoted, swelling in hair follicles and stem cells in hair papilla parts can be proliferated and differentiated, the hair follicles can enter a growth phase, hair growth is accelerated, and the problem of alopecia or hair scarcity is solved.
Description
Technical Field
The invention relates to the technical field of medical preparations, in particular to a composition and application thereof.
Background
Alopecia and sub-health problems with thin hair tend to become increasingly younger, which can seriously affect an individual's mental state and quality of life. Alopecia can be classified into three types according to the theory of cases, the first type is androgenic alopecia (AGA), which is usually seen in young and middle-aged men. The second is alopecia areata, commonly called ghost shaving head, which can occur at any age, but is common in young and strong years, and the incidence rate of both sexes is not obviously different. The third is alopecia due to stress, which is a loss of hair due to mental anxiety or working stress, and can occur at any age. Thinning may be due to the above-mentioned hair loss problems, loss of nutrients to the body, prolonged exposure of the hair to the sun, wind or often a dry environment.
Most of the products related to alopecia in the market are mainly used for preventing alopecia, and only a small part of the products are medicines or external preparations prepared from traditional Chinese medicines such as sesame, fleece-flower root and the like, but the using effect is not obvious.
Disclosure of Invention
The present invention is directed to a composition and its use to solve one or more of the problems of the prior art and to provide at least one useful alternative or creation.
In a first aspect, the invention provides a novel use of the EGFR activator NSC 228155. NSC228155 is generally used in the prior art at the cellular level, and is often used for in vitro cell culture or for pharmaceutical use in treating kidney damage. The inventor surprisingly finds that NSC228155 can be applied to the preparation of external medicines, cosmetics or daily chemical products in the research process to solve the problem of alopecia or hair scarcity. NSC228155, after penetrating the epidermis, rapidly penetrates the cell membrane and disperses in the cytoplasm and the nucleus, binds to the dimerization domain II of the sfegfr, regulates the tyrosine phosphorylation of the EGFR, and stimulates the EGFR in the hair follicle. After EGFR is combined, a series of biochemical activities in cells can be caused, epidermis and epithelial cells can be stimulated, epidermis hyperplasia and keratinization can be promoted, cell division, particularly hair follicle cells, can be strongly promoted, swelling in hair follicles and stem cells in hair papilla parts can be proliferated and differentiated, the hair follicles can enter a growth phase, hair growth is accelerated, and the problem of alopecia or hair scarcity is solved.
Further, the medicine, cosmetic or daily chemical product is an external preparation, an implant preparation, an injection preparation or a transdermal preparation. Since the targeted site of administration is hair follicle cells located in the epithelium, a type of topical agent is needed to help NSC228155 more readily penetrate the epidermis, deep into the epithelial layer.
Further, the pharmaceutical, cosmetic or daily chemical product is used for preventing/improving alopecia or hair thinning problem. The alopecia or hair rarity includes male hormone alopecia and alopecia areata process pressure type alopecia.
The second aspect of the invention provides an NSC228155 transdermal preparation, which comprises the NSC228155 and a transdermal enhancer or a transdermal absorption carrier which are mixed, wherein the mass concentration of the NSC228155 is 0.001-0.1 mg/L.
Further, the transdermal enhancer comprises one or more of thiaketone, azone compounds, N-dimethyl aminoacetic ester, fatty acid, fatty alcohol, cyclodextrin, terpenes, alcohol compounds, Borneolum Syntheticum, menthol, eucalyptus oil, and ethanol.
Further, the NSC228155 transdermal preparation also comprises a cosolvent, wherein the cosolvent comprises one or more of polyethylene glycol, tween, span, peregal and hydrogenated castor oil.
Further, the transdermal absorption carrier comprises one or more of liposome, transfersome, ethosome and microemulsion.
Different from the known application of NSC228155 serving as an EGFR activator, the technical scheme uses NSC228155 to stimulate the division of hair follicle cells in epithelium and directly apply the cell to the hair follicle through a transdermal preparation to promote the proliferation and differentiation of stem cells in the hair follicle bulge and hair papilla part, so as to promote the hair follicle to enter the anagen phase and promote the hair growth.
Drawings
FIG. 1 is an observation image of mice in the test group in example 1;
FIG. 2 is an observation image of a control group mouse in example 1;
FIG. 3 is a histogram of the change in color of the backs of mice in the experimental and control groups.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to specific embodiments, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1 mouse Back Hair irritation test
C57 mice had skin follicles in the back in telogen phase at 7-12 weeks, with the skin pink; when the hair follicle enters the anagen phase, the back skin appears black due to proliferation and secretion of melanin by melanocytes. Therefore, the hair on the back skin of the mouse can be removed after the administration, and the color of the back skin can be observed, so that whether the back skin of the mouse enters the anagen phase and the degree of the back skin entering the anagen phase can be judged.
Preparation of reagents: 0.1mg of EGFR agonist NSC228155 is taken, 100ml of mixed solution of PEG-400 and absolute ethyl alcohol in a volume ratio of 1:1 is taken as a solvent, and NSC228155 working solution is prepared for standby. The blank control was administered with the same mixture of PEG-400 and absolute ethanol as the blank control.
The test steps are as follows:
(1) 10 8 week-old C57 mice were randomly divided into two groups of 5 mice each.
(2) One group of mice was used as a test group and was transdermally administered twice a day, 400. mu.l each time, using NSC228155 working solution. The hair on the back of the mouse is combed by dipping cotton swab in water each time, the skin on the back is exposed, and the working solution is dripped into the skin. Another group of mice served as a control group and blank control was given transdermally twice daily by the same method, 400. mu.l each time.
(3) After 15 days of continuous administration, hair was removed from the backs of the two groups of mice, and changes in the skin on the backs were observed to count the area ratio of the black parts on the backs, respectively. As shown in FIGS. 1 and 2, the average of the skin darkening rate of the back of the test group was 48% and the average of the skin darkening rate of the back of the control group was 10% after 15 consecutive days of administration, respectively. Statistics of the back color changes of two groups of mice are shown in fig. 3, and the experimental group obviously advances into the anagen phase, which shows that the transdermal preparation prepared from NSC228155 can advance the hair into the anagen phase and promote the hair growth.
It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Claims (8)
- Application of an EGFR activator NSC228155 in preparation of external medicines, cosmetics or daily chemical products.
- 2. The use according to claim 1, wherein the pharmaceutical, cosmetic or daily chemical product is an external preparation, an implant preparation, an injection preparation or a transdermal preparation.
- 3. Use according to claim 1, wherein the pharmaceutical, cosmetic or daily chemical product is used for preventing/ameliorating hair loss or hair thinning problems.
- 4. The use according to claim 3, wherein the hair loss or hair loss comprises androgenic alopecia, alopecia areata process pressure alopecia.
- 5. The NSC228155 transdermal preparation is characterized in that NSC228155 is mixed with a transdermal enhancer or a transdermal absorption carrier, and the mass concentration of the NSC228155 is 0.001-0.1 mg/L.
- 6. The NSC228155 transdermal preparation according to claim 5, wherein the transdermal enhancer comprises one or more of thiaketone, azone compound, N-dimethylamino acetate, fatty acid, fatty alcohol, cyclodextrin, terpenes, alcohol compound, borneol, menthol, eucalyptus oil, and ethanol.
- 7. The NSC228155 transdermal formulation according to claim 6, further comprising a cosolvent, wherein the cosolvent comprises one or more of polyethylene glycol, tween, span, peregal, hydrogenated castor oil.
- 8. The NSC228155 transdermal formulation according to claim 5, wherein the transdermal absorption carrier comprises one or more of liposome, transfersome, ethosome, and microemulsion.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111009764.3A CN113694063A (en) | 2021-08-31 | 2021-08-31 | Composition and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111009764.3A CN113694063A (en) | 2021-08-31 | 2021-08-31 | Composition and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113694063A true CN113694063A (en) | 2021-11-26 |
Family
ID=78657678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111009764.3A Pending CN113694063A (en) | 2021-08-31 | 2021-08-31 | Composition and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113694063A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114796120A (en) * | 2022-05-25 | 2022-07-29 | 中山大学 | Liposome for preventing hair loss and growing hair as well as preparation method and application thereof |
CN116036082A (en) * | 2023-01-12 | 2023-05-02 | 南京市儿童医院 | Application of NSC228155 in preparation of medicines for preventing and treating sepsis-related acute heart injury |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100120768A1 (en) * | 2006-09-28 | 2010-05-13 | David Steinberg | Methods, kits, and compositions for generating new hair follicles and growing hair |
CN111295188A (en) * | 2017-09-29 | 2020-06-16 | 加利福尼亚大学董事会 | Compositions and methods for regulating hair growth |
CN111358790A (en) * | 2019-12-25 | 2020-07-03 | 江苏省肿瘤医院 | Application of NSC228155 in preparation of medicine for preventing and treating acute kidney injury |
CN112592884A (en) * | 2021-03-05 | 2021-04-02 | 北京科途医学科技有限公司 | Human EGFR20ins lung cancer organoid and culture method, culture medium and application thereof |
-
2021
- 2021-08-31 CN CN202111009764.3A patent/CN113694063A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100120768A1 (en) * | 2006-09-28 | 2010-05-13 | David Steinberg | Methods, kits, and compositions for generating new hair follicles and growing hair |
CN111295188A (en) * | 2017-09-29 | 2020-06-16 | 加利福尼亚大学董事会 | Compositions and methods for regulating hair growth |
CN111358790A (en) * | 2019-12-25 | 2020-07-03 | 江苏省肿瘤医院 | Application of NSC228155 in preparation of medicine for preventing and treating acute kidney injury |
CN112592884A (en) * | 2021-03-05 | 2021-04-02 | 北京科途医学科技有限公司 | Human EGFR20ins lung cancer organoid and culture method, culture medium and application thereof |
Non-Patent Citations (5)
Title |
---|
KINGSTON K. L. MAK等: "Epidermal Growth Factor as a Biologic Switch in Hair Growth Cycle", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
VEHARY SAKANYAN等: "Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor(EGFR) in cancer cells", 《SCIENTIFIC REPORTS》 * |
YING XIA等: "Epidermal growth factor promotes mesenchymal stem cell-mediated wound healing and hair follicle regeneration", 《INT J CLIN EXP PATHOL》 * |
YUFENG LIN等: "Jagged1 and Epidermal Growth Factor Promoted Androgen-suppressed Mouse Hair Growth In Vitro and In Vivo", 《FRONTIERS IN PHARMACOLOGY》 * |
牟笑笑 等: "溶血磷脂酸在皮肤损伤疾病中的作用及其分子机制", 《中国生物化学与分子生物学报》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114796120A (en) * | 2022-05-25 | 2022-07-29 | 中山大学 | Liposome for preventing hair loss and growing hair as well as preparation method and application thereof |
CN114796120B (en) * | 2022-05-25 | 2024-04-02 | 中山大学 | Anti-hair loss hair-growing liposome and preparation method and application thereof |
CN116036082A (en) * | 2023-01-12 | 2023-05-02 | 南京市儿童医院 | Application of NSC228155 in preparation of medicines for preventing and treating sepsis-related acute heart injury |
CN116036082B (en) * | 2023-01-12 | 2024-05-07 | 南京市儿童医院 | Application of NSC228155 in preparation of medicines for preventing and treating sepsis-related acute heart injury |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5663160A (en) | Cosmetic or dermatological composition containing at least one saponin of the ginsenoside type, and its applications, especially for treating the hair | |
AU2004218468B2 (en) | Method for increasing hair growth | |
Bazzano et al. | Topical tretinoin for hair growth promotion | |
CN113694063A (en) | Composition and application thereof | |
US20020048558A1 (en) | Topical delivery systems for active agents | |
KR101467568B1 (en) | Pharmaceutical solution containing minoxidil with enhanced dermal retention and hair growing effect | |
KR101199580B1 (en) | Nanoemulsion for topical administration | |
CN112516006A (en) | Nanometer composition with hair loss prevention, hair growth promotion, hair fixing and hair blackening functions and preparation method and application thereof | |
CN101365411A (en) | Topical administration carrier composition and therapeutic formulations comprising same | |
US6203782B1 (en) | Method and product for promoting hair growth and treating skin conditions | |
WO2016046848A2 (en) | Novel formulation of concentrated natural actives in oil-water microemulsion for hair fall prevention and increase in hair density | |
CN111973607A (en) | Compound external preparation for preventing and treating alopecia and promoting hair growth | |
EP2255782A1 (en) | Composition for the prevention or treatment of hair loss, and method of preparation | |
JP3555085B2 (en) | Use of simaluba extract for reducing mottled skin pigmentation or enhancing the protective function of the skin or for preparing a skin cell medium and the composition thus obtained | |
KR20080038710A (en) | Epidermal emulsion composition for treating a bald containing minoxidil and tretinoin | |
EP0659080B1 (en) | Method for the treatment of hair loss | |
JPH1192378A (en) | Hair tonic liquid for external use | |
JP2001288047A (en) | Composition for scalp and hair | |
JP3496896B2 (en) | Hair restorer and hair cosmetic | |
KR20020018566A (en) | Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophospholipids and uses thereof | |
JPH11255621A (en) | Cosmetic for scalp and hair | |
EP1080719A2 (en) | Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophosholipids | |
CN116077557B (en) | Composition for treating alopecia areata and application thereof | |
CN115778832B (en) | Hair growth preparation and preparation method thereof | |
CN112043627B (en) | Amino acid solution composition for hair growth and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211126 |
|
RJ01 | Rejection of invention patent application after publication |